{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:50:07Z","timestamp":1790027407745,"version":"4.0.1"},"publisher-location":"Cham","reference-count":101,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030203146","type":"print"},{"value":"9783030203153","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-20315-3_6","type":"book-chapter","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T05:05:44Z","timestamp":1563339944000},"page":"87-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Thrombotic Risk from Chemotherapy and Other Cancer Therapies"],"prefix":"10.1007","author":[{"given":"M. D.","family":"Debbie Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Alfred Ian Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"25","key":"6_CR1","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT Sorensen","year":"2000","unstructured":"Sorensen HT et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846\u20131850","journal-title":"N Engl J Med"},{"issue":"3","key":"6_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA et al (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119(3):648\u2013655","journal-title":"Cancer"},{"issue":"8","key":"6_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB et al (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70(8):926\u2013938","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"6_CR4","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF et al (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712\u20131723","journal-title":"Blood"},{"issue":"6","key":"6_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809\u2013815","journal-title":"Arch Intern Med"},{"issue":"9793","key":"6_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784","journal-title":"Lancet"},{"issue":"34","key":"6_CR7","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490\u20135505","journal-title":"J Clin Oncol"},{"issue":"8096","key":"6_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(78)91668-9","volume":"2","author":"K Nevasaari","year":"1978","unstructured":"Nevasaari K, Heikkinen M, Taskinen PJ (1978) Tamoxifen and thrombosis. Lancet 2(8096):946\u2013947","journal-title":"Lancet"},{"issue":"8177","key":"6_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(80)91538-X","volume":"1","author":"J Conard","year":"1980","unstructured":"Conard J et al (1980) l-asparaginase, antithrombin III, and thrombosis. Lancet 1(8177):1091","journal-title":"Lancet"},{"issue":"3","key":"6_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cncr.20347","volume":"101","author":"SR Deitcher","year":"2004","unstructured":"Deitcher SR, Gomes MP (2004) The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101(3):439\u2013449","journal-title":"Cancer"},{"issue":"9169","key":"6_CR11","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993\u20132000","journal-title":"Lancet"},{"issue":"29","key":"6_CR12","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27(29):4865\u20134873","journal-title":"J Clin Oncol"},{"issue":"10","key":"6_CR13","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","volume":"110","author":"AA Khorana","year":"2007","unstructured":"Khorana AA et al (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339\u20132346","journal-title":"Cancer"},{"issue":"5","key":"6_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","volume":"118","author":"TC Haddad","year":"2006","unstructured":"Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118(5):555\u2013568","journal-title":"Thromb Res"},{"issue":"2","key":"6_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1358863X14568705","volume":"20","author":"P Oppelt","year":"2015","unstructured":"Oppelt P, Betbadal A, Nayak L (2015) Approach to chemotherapy-associated thrombosis. Vasc Med 20(2):153\u2013161","journal-title":"Vasc Med"},{"issue":"9336","key":"6_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336):817\u2013824","journal-title":"Lancet"},{"issue":"18","key":"6_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"6_CR18","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529\u20131542","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"6_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","volume":"89","author":"B Fisher","year":"1997","unstructured":"Fisher B et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89(22):1673\u20131682","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"6_CR20","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1002\/cncr.24508","volume":"115","author":"RK Hernandez","year":"2009","unstructured":"Hernandez RK et al (2009) Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115(19):4442\u20134449","journal-title":"Cancer"},{"issue":"13","key":"6_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/jnci\/djj262","volume":"98","author":"N Abramson","year":"2006","unstructured":"Abramson N et al (2006) Effect of Factor V Leiden and prothrombin G20210\u2192A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 98(13):904\u2013910","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","volume":"111","author":"A Decensi","year":"2005","unstructured":"Decensi A et al (2005) Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111(5):650\u2013656","journal-title":"Circulation"},{"issue":"13","key":"6_CR23","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/jnci\/djq211","volume":"102","author":"JE Garber","year":"2010","unstructured":"Garber JE et al (2010) Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 102(13):942\u2013949","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"6_CR24","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1200\/JCO.2003.10.111","volume":"21","author":"C Duggan","year":"2003","unstructured":"Duggan C et al (2003) Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 21(19):3588\u20133593","journal-title":"J Clin Oncol"},{"issue":"4","key":"6_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.thromres.2010.10.025","volume":"127","author":"A Eroglu","year":"2011","unstructured":"Eroglu A, Akar N (2011) Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifen-associated thromboembolism in breast cancer patients. Thromb Res 127(4):384\u2013385","journal-title":"Thromb Res"},{"issue":"13","key":"6_CR26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.2010.32.2933","volume":"29","author":"A Hackshaw","year":"2011","unstructured":"Hackshaw A et al (2011) Long-term benefits of 5\u00a0years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50\u00a0years of age with early breast cancer. J Clin Oncol 29(13):1657\u20131663","journal-title":"J Clin Oncol"},{"key":"6_CR27","doi-asserted-by":"crossref","unstructured":"Ettinger B et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282(7):637\u2013645","DOI":"10.1001\/jama.282.7.637"},{"issue":"2","key":"6_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1160\/TH07-07-0468","volume":"99","author":"J Adomaityte","year":"2008","unstructured":"Adomaityte J, Farooq M, Qayyum R (2008) Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 99(2):338\u2013342","journal-title":"Thromb Haemost"},{"issue":"23","key":"6_CR29","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727\u20132741","journal-title":"JAMA"},{"key":"6_CR30","doi-asserted-by":"crossref","unstructured":"Goss PE et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262\u20131271","DOI":"10.1093\/jnci\/dji250"},{"issue":"9324","key":"6_CR31","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131\u20132139","journal-title":"Lancet"},{"issue":"21","key":"6_CR32","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20(21):4319\u20134323","journal-title":"J Clin Oncol"},{"issue":"5","key":"6_CR33","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5):1614\u20131615","journal-title":"Blood"},{"issue":"2","key":"6_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414\u2013423","journal-title":"Leukemia"},{"issue":"8","key":"6_CR35","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","volume":"28","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA et al (2014) Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28(8):1573\u20131585","journal-title":"Leukemia"},{"issue":"3","key":"6_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-2003-40965","volume":"29","author":"M Zangari","year":"2003","unstructured":"Zangari M et al (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29(3):275\u2013282","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"6_CR37","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"R Knight","year":"2006","unstructured":"Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079\u20132080","journal-title":"N Engl J Med"},{"issue":"13","key":"6_CR38","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV et al (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26(13):2171\u20132177","journal-title":"J Clin Oncol"},{"issue":"2","key":"6_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","volume":"11","author":"M Zangari","year":"2011","unstructured":"Zangari M et al (2011) Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk 11(2):228\u2013236","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"31","key":"6_CR40","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","volume":"33","author":"JP Leonard","year":"2015","unstructured":"Leonard JP et al (2015) Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 33(31):3635\u20133640","journal-title":"J Clin Oncol"},{"key":"6_CR41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood.V130.Suppl_1.221.677","volume":"130","author":"S Yamshon","year":"2017","unstructured":"Yamshon S et al (2017) Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide. Blood 130:122","journal-title":"Blood"},{"issue":"15_suppl","key":"6_CR42","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1200\/jco.2008.26.15_suppl.7084","volume":"26","author":"N. A. Brandenburg","year":"2008","unstructured":"Brandenburg NA et al (2008) Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: incidence and risk factors. J Clin Oncol 15_Suppl:7084","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"6_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1538-7933.2003.00573.x","volume":"2","author":"V Kaushal","year":"2004","unstructured":"Kaushal V et al (2004) Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2(2):327\u2013334","journal-title":"J Thromb Haemost"},{"issue":"8","key":"6_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/MBC.0b013e3283642ee2","volume":"24","author":"WZ Abdullah","year":"2013","unstructured":"Abdullah WZ et al (2013) Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood Coagul Fibrinolysis 24(8):893\u2013895","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl 1","key":"6_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000073282","volume":"33","author":"F Rodeghiero","year":"2003","unstructured":"Rodeghiero F, Elice F (2003) Thalidomide and thrombosis. Pathophysiol Haemost Thromb 33(Suppl 1):15\u201318","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"9","key":"6_CR46","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00277-004-0891-6","volume":"83","author":"A Corso","year":"2004","unstructured":"Corso A et al (2004) Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83(9):588\u2013591","journal-title":"Ann Hematol"},{"issue":"5","key":"6_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1600-0609.2006.00733.x","volume":"77","author":"P Zappasodi","year":"2006","unstructured":"Zappasodi P et al (2006) Thrombomodulin levels are not modified during thalidomide treatment. Eur J Haematol 77(5):453\u2013454","journal-title":"Eur J Haematol"},{"issue":"3","key":"6_CR48","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","volume":"115","author":"R. Pal","year":"2009","unstructured":"Pal R et al (2010) Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 115(3):605\u2013614","journal-title":"Blood"},{"issue":"5","key":"6_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/2042098612452291","volume":"3","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Palladino C (2012) Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf 3(5):255\u2013266","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"6_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","volume":"13","author":"M Zangari","year":"2002","unstructured":"Zangari M et al (2002) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13(3):187\u2013192","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"6_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MBC.0b013e32832b27e6","volume":"20","author":"GP Talamo","year":"2009","unstructured":"Talamo GP et al (2009) Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis 20(5):337\u2013339","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"6_CR52","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ajh.23504","volume":"88","author":"T Bagratuni","year":"2013","unstructured":"Bagratuni T et al (2013) Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 88(9):765\u2013770","journal-title":"Am J Hematol"},{"issue":"13","key":"6_CR53","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","volume":"112","author":"DC Johnson","year":"2008","unstructured":"Johnson DC et al (2008) Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112(13):4924\u20134934","journal-title":"Blood"},{"issue":"6","key":"6_CR54","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.12522","volume":"93","author":"M Zangari","year":"2008","unstructured":"Zangari M et al (2008) Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 93(6):953\u2013954","journal-title":"Haematologica"},{"issue":"4","key":"6_CR55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A. Larocca","year":"2011","unstructured":"Larocca A et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933\u2013939; quiz 1093","journal-title":"Blood"},{"issue":"8","key":"6_CR56","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo A et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29(8):986\u2013993","journal-title":"J Clin Oncol"},{"issue":"17","key":"6_CR57","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","volume":"31","author":"GH Lyman","year":"2013","unstructured":"Lyman GH et al (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189\u20132204","journal-title":"J Clin Oncol"},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","volume":"2010","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY (2010) Thrombosis in multiple myeloma. Hematol Am Soc Hematol Educ Program 2010:437\u2013444","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"6_CR59","first-page":"281","volume":"75","author":"EW Greeno","year":"1996","unstructured":"Greeno EW, Bach RR, Moldow CF (1996) Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 75(2):281\u2013289","journal-title":"Lab Invest"},{"issue":"2","key":"6_CR60","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1046\/j.1365-2141.2001.03095.x","volume":"115","author":"J Wang","year":"2001","unstructured":"Wang J et al (2001) Thrombogenic role of cells undergoing apoptosis. Br J Haematol 115(2):382\u2013391","journal-title":"Br J Haematol"},{"issue":"2","key":"6_CR61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.1988.6.2.276","volume":"6","author":"JS Rogers 2nd","year":"1988","unstructured":"Rogers JS 2nd et al (1988) Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6(2):276\u2013281","journal-title":"J Clin Oncol"},{"issue":"1","key":"6_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12885-016-3032-4","volume":"17","author":"MN Zahir","year":"2017","unstructured":"Zahir MN et al (2017) Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy\u2014a cohort study. BMC Cancer 17(1):57","journal-title":"BMC Cancer"},{"issue":"35","key":"6_CR63","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","volume":"30","author":"S Seng","year":"2012","unstructured":"Seng S et al (2012) Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 30(35):4416\u20134426","journal-title":"J Clin Oncol"},{"key":"6_CR64","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.V128.22.2598.2598","volume":"128","author":"B Pulluri","year":"2016","unstructured":"Pulluri B et al (2016) Risk factors for venous thromboembolism in metastatic colon cancer patients in the contemporary treatment era: a SEER-Medicare data analysis. Blood 128:2598","journal-title":"Blood"},{"issue":"2","key":"6_CR65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archinte.164.2.190","volume":"164","author":"HM Otten","year":"2004","unstructured":"Otten HM et al (2004) Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164(2):190\u2013194","journal-title":"Arch Intern Med"},{"issue":"3","key":"6_CR66","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1200\/JCO.1994.12.3.560","volume":"12","author":"JL Grem","year":"1994","unstructured":"Grem JL et al (1994) Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 12(3):560\u2013568","journal-title":"J Clin Oncol"},{"issue":"2","key":"6_CR67","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229\u2013237","journal-title":"J Clin Oncol"},{"issue":"7","key":"6_CR68","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/1097-0142(19890401)63:7<1303::AID-CNCR2820630713>3.0.CO;2-F","volume":"63","author":"SE Feffer","year":"1989","unstructured":"Feffer SE, Carmosino LS, Fox RL (1989) Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 63(7):1303\u20131307","journal-title":"Cancer"},{"issue":"1","key":"6_CR69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0002-9343(90)90093-S","volume":"89","author":"RL Edwards","year":"1990","unstructured":"Edwards RL et al (1990) Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 89(1):25\u201328","journal-title":"Am J Med"},{"key":"6_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","volume":"15","author":"A Polk","year":"2014","unstructured":"Polk A et al (2014) A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 15:47","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"6_CR71","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/1097-0142(19801001)46:7<1548::AID-CNCR2820460709>3.0.CO;2-7","volume":"46","author":"JR Priest","year":"1980","unstructured":"Priest JR et al (1980) Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 46(7):1548\u20131554","journal-title":"Cancer"},{"issue":"4","key":"6_CR72","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","volume":"152","author":"RF Grace","year":"2011","unstructured":"Grace RF et al (2011) The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152(4):452\u2013459","journal-title":"Br J Haematol"},{"issue":"2","key":"6_CR73","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0609.1992.tb00032.x","volume":"49","author":"L Gugliotta","year":"1992","unstructured":"Gugliotta L et al (1992) Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving l-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol 49(2):63\u201366","journal-title":"The GIMEMA Group. Eur J Haematol"},{"issue":"26","key":"6_CR74","first-page":"1643","volume":"307","author":"GS Lederman","year":"1982","unstructured":"Lederman GS (1982) Stroke due to treatment with l-asparaginase in an adult. N Engl J Med 307(26):1643","journal-title":"N Engl J Med"},{"issue":"2","key":"6_CR75","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.11042","volume":"97","author":"LG Mitchell","year":"2003","unstructured":"Mitchell LG et al (2003) A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97(2):508\u2013516","journal-title":"Cancer"},{"issue":"25","key":"6_CR76","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1182\/blood-2009-07-231084","volume":"114","author":"LS Abbott","year":"2009","unstructured":"Abbott LS et al (2009) The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 114(25):5146\u20135151","journal-title":"Blood"},{"issue":"4","key":"6_CR77","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1160\/TH12-11-0845","volume":"109","author":"MN Lauw","year":"2013","unstructured":"Lauw MN et al (2013) Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost 109(4):633\u2013642","journal-title":"Thromb Haemost"},{"issue":"5","key":"6_CR78","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/MPH.0b013e31828dc614","volume":"35","author":"N Santoro","year":"2013","unstructured":"Santoro N et al (2013) Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. J Pediatr Hematol Oncol 35(5):348\u2013355","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"6_CR79","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","volume":"108","author":"V Caruso","year":"2006","unstructured":"Caruso V et al (2006) Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108(7):2216\u20132222","journal-title":"Blood"},{"issue":"17","key":"6_CR80","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.2217\/fon.15.114","volume":"11","author":"G Goyal","year":"2015","unstructured":"Goyal G, Bhatt VR (2015) l-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Future Oncol 11(17):2459\u20132470","journal-title":"Future Oncol"},{"issue":"11","key":"6_CR81","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ajh.24130","volume":"90","author":"MA Couturier","year":"2015","unstructured":"Couturier MA et al (2015) Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience. Am J Hematol 90(11):986\u2013991","journal-title":"Am J Hematol"},{"issue":"11","key":"6_CR82","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.3109\/10428194.2016.1165815","volume":"57","author":"K Farrell","year":"2016","unstructured":"Farrell K et al (2016) An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leuk Lymphoma 57(11):2568\u20132574","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6_CR83","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3324\/haematol.12948","volume":"93","author":"M. Hunault-Berger","year":"2008","unstructured":"Hunault-Berger M et al (2008) Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 93(10):1488\u20131494","journal-title":"Haematologica"},{"issue":"2","key":"6_CR84","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/pbc.21222","volume":"50","author":"B Meister","year":"2008","unstructured":"Meister B et al (2008) Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 50(2):298\u2013303","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"6_CR85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60\u201365","journal-title":"J Clin Oncol"},{"issue":"19","key":"6_CR86","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277\u20132285","journal-title":"JAMA"},{"issue":"4","key":"6_CR87","first-page":"221","volume":"9","author":"AK Alahmari","year":"2016","unstructured":"Alahmari AK et al (2016) Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of randomized controlled trials. Am Health Drug Benefits 9(4):221\u2013232","journal-title":"Am Health Drug Benefits"},{"issue":"16","key":"6_CR88","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232\u20131239","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"6_CR89","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cncr.29169","volume":"121","author":"JN Patel","year":"2015","unstructured":"Patel JN et al (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121(7):1025\u20131031","journal-title":"Cancer"},{"issue":"10","key":"6_CR90","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/ijc.30280","volume":"139","author":"M Miroddi","year":"2016","unstructured":"Miroddi M et al (2016) Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab). Int J Cancer 139(10):2370\u20132380","journal-title":"Int J Cancer"},{"issue":"1","key":"6_CR91","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/COC.0b013e31819cccaf","volume":"33","author":"JV Roddy","year":"2010","unstructured":"Roddy JV et al (2010) Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. Am J Clin Oncol 33(1):36\u201342","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"6_CR92","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11523-017-0496-3","volume":"12","author":"A Kuk","year":"2017","unstructured":"Kuk A et al (2017) Retrospective evaluation of thromboembolism risk in ovarian cancer patients treated with bevacizumab. Target Oncol 12(4):495\u2013503","journal-title":"Target Oncol"},{"issue":"7","key":"6_CR93","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.29168","volume":"121","author":"TG DeLoughery","year":"2015","unstructured":"DeLoughery TG, Beer TM (2015) Bevicizumab and thrombosis: some answers but questions remain. Cancer 121(7):975\u2013977","journal-title":"Cancer"},{"issue":"1","key":"6_CR94","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/157016110790226660","volume":"8","author":"P Ferroni","year":"2010","unstructured":"Ferroni P et al (2010) Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol 8(1):102\u2013113","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"6_CR95","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1002\/ijc.27979","volume":"132","author":"WX Qi","year":"2013","unstructured":"Qi WX et al (2013) Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 132(12):2967\u20132974","journal-title":"Int J Cancer"},{"key":"6_CR96","doi-asserted-by":"crossref","unstructured":"Tonia T et al (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:Cd003407","DOI":"10.1002\/14651858.CD003407.pub5"},{"key":"6_CR97","doi-asserted-by":"crossref","unstructured":"Bohlius J et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev (3):CD003407","DOI":"10.1002\/14651858.CD003407.pub4"},{"issue":"12","key":"6_CR98","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/cncr.21496","volume":"104","author":"AA Khorana","year":"2005","unstructured":"Khorana AA et al (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822\u20132829","journal-title":"Cancer"},{"issue":"1","key":"6_CR99","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3324\/haematol.2011.051755","volume":"97","author":"SW Smith","year":"2012","unstructured":"Smith SW et al (2012) Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 97(1):15\u201320","journal-title":"Haematologica"},{"issue":"9","key":"6_CR100","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","volume":"173","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir SA et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173(9):743\u2013752","journal-title":"JAMA Intern Med"},{"key":"6_CR101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.critrevonc.2017.03.006","volume":"113","author":"JB Guy","year":"2017","unstructured":"Guy JB et al (2017) Venous thromboembolism in radiation therapy cancer patients: findings from the RIETE registry. Crit Rev Oncol Hematol 113:83\u201389","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Cancer Treatment and Research","Thrombosis and Hemostasis in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-20315-3_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:54:06Z","timestamp":1663980846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-20315-3_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030203146","9783030203153"],"references-count":101,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-20315-3_6","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"18 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}